Cleerly does a thorough evaluation of every coronary artery and branch, going above and beyond the standard methods of detecting heart disease. By identifying, characterizing, and quantifying plaque formation, Cleerly's AI-enabled review of Coronary CT Angiography assists doctors in assessing a patient's risk of a heart attack and creating a treatment strategy to promote heart health.
Instead of using indirect indicators like surrogates, symptoms, and disease sequelae as has traditionally been done, Cleerly's technology quantifies and characterizes coronary artery disease (CAD) to help customize therapies to a patient's actual condition. Innovative digital and print solutions from Cleerly are also available, transforming complex imaging data into therapeutic insights that clinicians and their patients can use.
Cardiology has essentially been "sick-care" for more than 50 years, with an emphasis on the signs and symptoms of atherosclerosis-related heart disease rather than the disease itself. Data from clinical trials conducted over a ten-year period have shown that the most important factor is the kind of atherosclerotic plaque accumulation. It's time to tackle the issue head-on, assess the underlying ailment, and treat it precisely rather than waiting for diminished blood flow or obstructions.
Your coronary arteries and branches are all thoroughly evaluated by Cleerly's analysis. Identifies, describes, and precisely counts plaques to help your doctor determine your risk of having a heart attack and to direct your treatment regimen in order to keep your heart healthy.
James K. Min, MD, is the former director of the Dalio Institute of Cardiovascular Imaging (ICI) at New York-Presbyterian and a former professor of radiology and medicine at Weill Cornell Medical College. His clinical interests are in the prevention of cardiovascular disease and cardiovascular imaging. He is a board-certified cardiologist.
Min has produced more than 500 peer-reviewed publications with a clinical and scientific focus on coronary artery disease, some of which were supported by multiple grants from the National Institutes of Health and the Dalio Foundation. The ACCURACY, CONFIRM, CONSERVE, CREDENCE, ICONIC, and PARADIGM trials are just a few of the notable multicenter clinical studies and registries on which Min has worked as the principal investigator. In addition, Min oversees a cutting-edge coronary computed tomography core laboratory for many multicenter clinical trials, including the PACIFIC and ISCHEMIA trials.
The creation, approval, and distribution of Cleerly's goods and services give Min the chance to apply the extensive clinical trial research he has been conducting for the past 17 years to the development of brand-new, as-yet-unavailable treatments for coronary heart disease. Min received his BA from the University of Chicago, and his medical degree from Temple University Medical School. He completed his internship, residency and cardiovascular medicine fellowship at the University of Chicago Hospitals.
With a death from cardiovascular illness occurring every 1.7 seconds, sudden coronary death from deadly heart attacks has remained the leading cause of mortality and morbidity in the globe for the past 50 years.
Cleerly has previously concentrated on illness surrogates (such as cholesterol), disease symptoms (such as chest discomfort or shortness of breath), or disease sequelae (like ischemia or stenosis). However, the majority of coronary lesions that result in heart attacks are silent, undiagnosed, and do not result in ischemia or stenosis. It's time to quantify true disease rather than merely disease-related indicators.
With the help of Cleerly technology, atherosclerotic plaque in the arteries can be identified and quantified, revealing both its quantity and type. Plaque type has been demonstrated to be the most accurate predictor of the likelihood that your patient will experience an approaching cardiac event and the strongest classifier of future heart attack risk. With dietary modifications and medical treatment, high-risk plaques have been stabilized by changing from non-calcified fatty plaques to calcified stable plaques. It has been demonstrated that calcification of non-calcified high-risk plaques results in a low incidence of significant adverse cardiovascular events.
Cleerly offers a transformative digital care pathway for the evaluation and management of Coronary Artery Disease (CAD). Leveraging latest-generation artificial intelligence (AI) frameworks, Cleerly’s solutions perform comprehensive and quantitative assessment of CAD, with clinical solutions delivered to imaging physicians, clinicians and patients.
Every day, Cleerly develops cutting-edge technology that revolutionizes how heart attacks and other cardiovascular diseases are prevented and treated. To do this, Cleerly devotes a lot of time and money to research and development. As part of a goal to safeguard the technologies that have made Cleerly an industry leader in the prevention and treatment of cardiovascular disease, the company has vigorously created a strong intellectual property portfolio to safeguard its research and development efforts.
“Our AI-enabled evaluation of Coronary CT Angiography identifies, characterizes, and quantifies plaque buildup to support physicians in determining a patient's risk of a heart attack and developing a treatment plan to improve heart health.”
Also Read: 20 Best Companies to Watch in 2022
Cleerly does a thorough evaluation of every coronary artery and branch, going above and beyond the standard methods of detecting heart disease. By identifying, characterizing, and quantifying plaque formation, Cleerly's AI-enabled review of Coronary CT Angiography assists doctors in assessing a patient's risk of a heart attack and creating a treatment strategy to promote heart health.
Instead of using indirect indicators like surrogates, symptoms, and disease sequelae as has traditionally been done, Cleerly's technology quantifies and characterizes coronary artery disease (CAD) to help customize therapies to a patient's actual condition. Innovative digital and print solutions from Cleerly are also available, transforming complex imaging data into therapeutic insights that clinicians and their patients can use.
Cardiology has essentially been "sick-care" for more than 50 years, with an emphasis on the signs and symptoms of atherosclerosis-related heart disease rather than the disease itself. Data from clinical trials conducted over a ten-year period have shown that the most important factor is the kind of atherosclerotic plaque accumulation. It's time to tackle the issue head-on, assess the underlying ailment, and treat it precisely rather than waiting for diminished blood flow or obstructions.
Your coronary arteries and branches are all thoroughly evaluated by Cleerly's analysis. Identifies, describes, and precisely counts plaques to help your doctor determine your risk of having a heart attack and to direct your treatment regimen in order to keep your heart healthy.
James K. Min, MD, is the former director of the Dalio Institute of Cardiovascular Imaging (ICI) at New York-Presbyterian and a former professor of radiology and medicine at Weill Cornell Medical College. His clinical interests are in the prevention of cardiovascular disease and cardiovascular imaging. He is a board-certified cardiologist.
Min has produced more than 500 peer-reviewed publications with a clinical and scientific focus on coronary artery disease, some of which were supported by multiple grants from the National Institutes of Health and the Dalio Foundation. The ACCURACY, CONFIRM, CONSERVE, CREDENCE, ICONIC, and PARADIGM trials are just a few of the notable multicenter clinical studies and registries on which Min has worked as the principal investigator. In addition, Min oversees a cutting-edge coronary computed tomography core laboratory for many multicenter clinical trials, including the PACIFIC and ISCHEMIA trials.
The creation, approval, and distribution of Cleerly's goods and services give Min the chance to apply the extensive clinical trial research he has been conducting for the past 17 years to the development of brand-new, as-yet-unavailable treatments for coronary heart disease. Min received his BA from the University of Chicago, and his medical degree from Temple University Medical School. He completed his internship, residency and cardiovascular medicine fellowship at the University of Chicago Hospitals.
With a death from cardiovascular illness occurring every 1.7 seconds, sudden coronary death from deadly heart attacks has remained the leading cause of mortality and morbidity in the globe for the past 50 years.
Cleerly has previously concentrated on illness surrogates (such as cholesterol), disease symptoms (such as chest discomfort or shortness of breath), or disease sequelae (like ischemia or stenosis). However, the majority of coronary lesions that result in heart attacks are silent, undiagnosed, and do not result in ischemia or stenosis. It's time to quantify true disease rather than merely disease-related indicators.
With the help of Cleerly technology, atherosclerotic plaque in the arteries can be identified and quantified, revealing both its quantity and type. Plaque type has been demonstrated to be the most accurate predictor of the likelihood that your patient will experience an approaching cardiac event and the strongest classifier of future heart attack risk. With dietary modifications and medical treatment, high-risk plaques have been stabilized by changing from non-calcified fatty plaques to calcified stable plaques. It has been demonstrated that calcification of non-calcified high-risk plaques results in a low incidence of significant adverse cardiovascular events.
Cleerly offers a transformative digital care pathway for the evaluation and management of Coronary Artery Disease (CAD). Leveraging latest-generation artificial intelligence (AI) frameworks, Cleerly’s solutions perform comprehensive and quantitative assessment of CAD, with clinical solutions delivered to imaging physicians, clinicians and patients.
Every day, Cleerly develops cutting-edge technology that revolutionizes how heart attacks and other cardiovascular diseases are prevented and treated. To do this, Cleerly devotes a lot of time and money to research and development. As part of a goal to safeguard the technologies that have made Cleerly an industry leader in the prevention and treatment of cardiovascular disease, the company has vigorously created a strong intellectual property portfolio to safeguard its research and development efforts.
“Our AI-enabled evaluation of Coronary CT Angiography identifies, characterizes, and quantifies plaque buildup to support physicians in determining a patient's risk of a heart attack and developing a treatment plan to improve heart health.”